Mexiletine and Digoxin Interaction

Understanding the Mexiletine and Digoxin Interaction

FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Mexiletine belongs to the Class IB Antiarrhythmic class and Digoxin belongs to the Cardiac Glycoside class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Mexiletine does not change the amount of digoxin in your blood or affect the heart's electrical signals when taken together. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Mexiletine has 14 total documented interactions on file in this dataset, and Digoxin has 120. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: These medications are generally safe to take together, but you should still follow your doctor's regular monitoring plan for your heart condition. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Mexiletine or Digoxin based on a web page, speak with your prescriber or pharmacist before making any change.